[Alphacalcidol in the treatment of osteopenic syndrome in patients with bronchial asthma].
To assess effectiveness of alphacalcidol in the treatment of osteopenic syndrome in patients with bronchial asthma (BA). 65 BA patients with low densitometric parameters of bone tissue density were examined for bone density, basic parameters of Ca-P metabolism and some markers of bone metabolism during 6-month therapy with alphacalcidol (alpha-D3-TEVA) in a dose 0.5-0.75 mcg/day. All the patients after 6 months of therapy experienced pain relief, normalization of calcium-phosphorus metabolism, lower risk of broken bones. Their bone tissue increased its density. Alphacalcidol has analgetic and antiresorptive properties. It effectively prevents and treats osteopenic syndrome in patients with bronchial asthma.